Skip to content
Screener

BioMarin Pharmaceuticals BMRN Q1 2026 earnings

Reported May 4, 2026 · After market close

Revenue$766.0MBeat by $13.5M
EPS$0.55Miss by $0.39
Revenue estimate$752.5M
EPS estimate$0.94

Next report

Oct 26, 2026 (in a month)
Revenue estimate$1.0B
EPS estimate$1.35

Financials

Q1 2026

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$10.86B-19.4%
Enterprise value$9.22B-29.3%
P/S3.4×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Segments

By product

See full
VOXZOGO$219.9M+2.9%
VIMIZIM$210.2M+11.6%
NAGLAZYME$130.1M+13.8%
PALYNZIQ$89.6M-4.0%
BRINEURA$47.1M+16.7%

By segment

See full
Reportable Segment$766.2M+2.8%

FAQ

When did BioMarin Pharmaceuticals report Q1 2026 earnings?
BioMarin Pharmaceuticals (BMRN) reported Q1 2026 earnings on May 4, 2026 after market close.
What were BioMarin Pharmaceuticals's Q1 2026 revenue and EPS?
BioMarin Pharmaceuticals reported revenue of $766.0M and eps of $0.55 for Q1 2026.
Did BioMarin Pharmaceuticals beat estimates in Q1 2026?
Revenue beat the consensus estimate of $752.5M by $13.5M. EPS missed the consensus estimate of $0.94 by $0.39.
How did BioMarin Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.8% from $745.1M a year earlier and eps declined 51.3% from $1.13.
Where can I find BioMarin Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001048477-26-000006) and the 10-Q periodic report (0001048477-26-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.